Tharimmune to Present at the Microcap Conference 2025
-
Trump fires homeland security chief Kristi Noem
-
Mideast war risks pulling more in as conflict boils over
-
Wales' James Botham 'sledged' by grandfather Ian Botham after Six Nations error
-
India hero Samson eyes 'one more' big knock in T20 World Cup final
-
Britney Spears detained on suspicion of driving while intoxicated
-
Grooming makes Crufts debut as UK dog show widens offer
-
Townsend insists Scots' focus solely on France not Six Nations title race
-
UK sends more fighter jets to Gulf: PM
-
EU to ban plant-based 'bacon' but veggie 'burgers' survive chop
-
Leagues Cup to hold matches in Mexico for first time
-
India reach T20 World Cup final after England fail in epic chase
-
Conservative Anglicans press opposition to Church's first woman leader
-
Sri Lanka takes control of Iranian ship fearing new US sub attack
-
Iran players sing anthem and salute at Women's Asian Cup
-
India beat England in high-scoring T20 World Cup semi-final
-
Mideast war traps 20,000 seafarers, 15,000 cruise passengers in Gulf
-
Italy bring back Brex to face England
-
French policeman to be tried over 2023 killing of teen
-
More flights take off despite continued fighting in Middle East
-
Ukraine, Russia free 200 POWs each
-
Middle East war halts work at WHO's Dubai emergency hub
-
Paramount's Ellison vows CNN editorial independence
-
US says attacks on alleged drug boats have spooked traffickers
-
Dempsey returns as Scotland shuffle pack for Six Nations clash against France
-
India pile up 253-7 against England in T20 World Cup semi-final
-
Wary Europeans pledge 'defensive' military aid in Mideast war
-
Oil prices rise, stocks drop as Middle East war stirs supply concerns
-
Seven countries to boycott Paralympics ceremony over Russia: organisers
-
UK's Crufts dog show opens with growing global appeal
-
PSG prepare for Chelsea clash with Monaco rematch
-
Google opens AI centre as Berlin defends US tech reliance
-
Second Iranian ship nears Sri Lanka after submarine attack
-
Portugal mourns acclaimed writer Antonio Lobo Antunes
-
Union loses fight against Tesla at German factory
-
Wales revel in being the underdogs, says skipper Lake
-
German school students rally against army recruitment drive
-
Wary European states pledge military aid for Cyprus, Gulf
-
Liverpool injuries frustrating Slot in tough season
-
Real Madrid will 'keep fighting' in title race, vows Arbeloa
-
Australia join South Korea in quarters of Women's Asian Cup
-
Stocks, oil climb as Middle East war stirs volatility
-
Kane to miss Bayern game against Gladbach with calf knock
-
Henman says Raducanu needs more physicality to rise up rankings
-
France recall fit-again Jalibert to face Scotland
-
Harry Styles fans head in one direction: to star's home village
-
Syrian jailed over stabbing at Berlin Holocaust memorial
-
Second Iranian ship heading to Sri Lanka after submarine attack
-
Middle East war spirals as Iran hits Kurds in Iraq
-
Norris hungrier than ever to defend Formula One world title
-
Fatherhood, sleep, T20 World Cup final: Henry's whirlwind journey
NYSE - LSE
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
